Clinical trial NCT03705065: Bupivacaine HCl PK and Safety in Augmentation Mammoplasty
Official title: A Phase 4, Randomized, Open-Label Study of the Pharmacokinetics and Tolerability of Bupivacaine HCl Following One of Two Routes of Administration in Subjects Undergoing Augmentation Mammoplasty
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Analgesia
Keywords: augmentation mammoplasty
Lead sponsor: Heron Therapeutics
Sponsor class: INDUSTRY
First posted: 2018-10-15
Enrollment: 30
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a Phase 4, randomized, open-label study of bupivacaine HCl administered either by instillation into the surgical site or by injection into the surgical site in subjects undergoing bilateral submuscular augmentation mammoplasty under general anesthesia.


Eligibility criteria: Inclusion Criteria:

* Is scheduled to undergo primary bilateral submuscular augmentation mammoplasty with saline or silicone smooth implants with a volume of 300 to 500 mL, inclusive.
* Has an American Society of Anesthesiologists Physical Status of I, II, or III.
* Female subjects are eligible only if not pregnant, not lactating, not planning to become pregnant during the study, sterile; or using acceptable contraceptives.

Exclusion Criteria:

* Has a planned concurrent surgical procedure (eg, mastopexy).
* Has a planned concurrent reconstructive procedure status post breast cancer therapy.
* Has a pre-existing concurrent acute or chronic painful physical/restrictive condition expected to require analgesic treatment in the postoperative period for pain that is not strictly related to the augmentation mammoplasty.
* Has a contraindication or a known or suspected history of hypersensitivity or clinically significant idiosyncratic reaction to required study medications.
* Has been administered bupivacaine within 5 days prior to the scheduled surgery.
* Has been administered any local anesthetic within 72 hours prior to the scheduled surgery.
* Has a medical condition such that, in the opinion of the Investigator, participating in the study would pose a health risk to the subject or confound the postoperative assessments.
* As per subject history and/or medical records, has active infection or is currently undergoing treatment for Hepatitis B, Hepatitis C, or human immunodeficiency virus (HIV).
* Has uncontrolled anxiety, psychiatric, or neurological disorder.
* Had a malignancy in the last year, with the exception of nonmetastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.
* Has a known or suspected history of drug abuse, a positive drug screen on the day of surgery, or a recent history of alcohol abuse. Note: Subjects with a positive drug screen who are taking an allowed, prescribed medication that is known to result in a positive drug test (eg, amphetamine and dextroamphetamine for attention-deficit/hyperactivity disorder, benzodiazepine for anxiety disorder) may be eligible for participation in the study at the discretion of the Sponsor. Subjects taking any marijuana (medical or recreational) are not allowed to participate in the study.
* Received an investigational product or device in a clinical trial within 30 days or within 5 elimination half-lives.
* Has undergone 3 or more surgeries within 12 months.
* Has a body mass index (BMI) \>35 kg/m2.

Primary outcomes:
measure: Maximum Observed Plasma Concentration (Cmax)
timeFrame: Baseline through 72 hours after start of study drug administration
measure: Area Under the Concentration-time Curve From Time 0 to the Last Collection Time After Study Drug Administration (AUC Last)
timeFrame: Baseline through 72 hours after start of study drug administration
measure: Area Under the Concentration-time Curve From Time 0 to Infinity After Study Drug Administration (AUC∞)
timeFrame: Baseline through 72 hours after start of study drug administration
measure: Time to Maximum Plasma Concentration (Tmax)
timeFrame: Baseline through 72 hours after start of study drug administration
measure: The Apparent Terminal Elimination Rate Constant (λz)
timeFrame: Baseline through 72 hours after start of study drug administration
measure: The Apparent Terminal Elimination Half-life (t1/2el)
timeFrame: Baseline through 72 hours after start of study drug administration
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: Hermann Drive Surgical Hospital
state: Texas
Study officials:
References: